Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

Journal:

The New England Journal of Medicine

Published:

2026-02-19

DOI:

10.1056/nejmoa2511674

Affiliations:

26

Authors:

26

Go to article

Institutions	Authors	Share
Merck - Rahway, United States of America (USA)	3.000000	0.12
Volga District Medical Center, Russia	1.000000	0.04
Necmettin Erbakan University, Turkey	1.000000	0.04
Parkview Health, United States of America (USA)	1.000000	0.04
Korea University Anam Hospital, South Korea	1.000000	0.04
Arthur J.E. Child Comprehensive Cancer Centre (Arthur Child), AHS, Canada	1.000000	0.04
Faculty of Medicine Siriraj Hospital, MU, Thailand	1.000000	0.04
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA)	1.000000	0.04
Astellas US LLC, United States of America (USA)	1.000000	0.04
Cleveland Clinic Taussig Cancer Center, United States of America (USA)	1.000000	0.04
Szpital Wojewódzki im. Św. Łukasza, Poland	1.000000	0.04
Gifu University, Japan	1.000000	0.04
Melvin and Bren Simon Comprehensive Cancer Center, United States of America (USA)	1.000000	0.04
University Cancer Center Hamburg (UCCH), UHH, Germany	1.000000	0.04
Cherkasy Regional Oncology, Ukraine	1.000000	0.04
Pfizer, United States of America (USA)	1.000000	0.04
Lviv Regional Oncology Dispensary, Ukraine	1.000000	0.04
Klinikum Stuttgart, Germany	1.000000	0.04
Hospital del Mar, Spain	1.000000	0.04
University Hospital Tübingen (UKT), Uni Tübingen, Germany	1.000000	0.04
Molecular Predictors and New Targets in Oncology, France	1.000000	0.04
The University of Chicago (UChicago), United States of America (USA)	1.000000	0.04
Karolinska Institute (KI), Sweden	0.500000	0.02
Maria Middelares General Hospital (AZ Maria Middelares), Belgium	0.500000	0.02
University of Antwerp (UA), Belgium	0.500000	0.02
Karolinska University Hospital, Sweden	0.500000	0.02

Interested in Oncology and Carcinogenesis?